Prostate-specific antigen

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 7, 2000, Pages 1399-1411

  Ornstein, David K ^a   Pruthi, Raj S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BLOOD; HUMAN; MALE; PATHOLOGY; PROSTATE TUMOR; REVIEW; URINE;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034574548     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.7.1399     Document Type: Article

References (94)

1. LILJA H: Prostate-specific antigen: molecular forms and the human kallikrein gene family. Br.J. Urol. (1997) 79(SuppI. iy.44-48. Good review of PSA biology.
2. DIAMANDIS EP.YU H: Non-prostatic sources of prostate-specific antigen. Urol. Clin. North Am. (1997) 24(2):275-282.
3. CATALONA WJ, SMITH DS, RATL1FF TL et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. A'. Engl.J.Med. (1991) 324(17):1156-ll6l. First demonstration that serum PSA testing can aid in early prostate cancer detection.
4. ARCANGELI CG, ORNSTEIN DK, KEETCH D\V, ANDRIOLE GL: Prostate-specific antigen as a screening test for prostate cancer. The United States experience. Urol. Clin. North Am. (1997) 24(2):299-306. Good review on the use of PSA testing for early detection.
5. SMITH DS, CATALONA WJ, HERSCHMAN JD: Longitudinal screening for prostate cancer with prostatespecific antigen. JAMA (1996) 276(l6):1309-1315. Results of large prostate cancer screening trial.
6. JACOBSEN SJ, KATUSIC SK, BERGSTRALH EJ et ah Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA (1995) 274(18):1445-1449.
7. POTOSKY AL, HARLAN LC, STANFORD JL ct a!.: Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. / Kail. Cancer Inst. (1999) 91(20):1719-1724.
8. WINGO PA, RIES LA, ROSENBERG HM, MILLER DS, EDWARDS BK: Cancer incidence and mortality, 1973-1995: a report card for the US. Cancer (1998) 82(6):1197-1207.
9. STEPHENSON RA, STANFORD JL: Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen. WorldJ. Urol. (1997) 15(6):331-335.
10. SMITH DS, CATALONA WJ: The nature of prostate cancer detected through prostate-specific antigen based screening./ Urol. (1994) 152(5 Pt 2):1732-1736.
11. CATALONA WJ, RICHIE JP, AHMANN FR et al.: Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer: results of a multicentcr clinical trial of 6,630 men./ {/roJ. (1994) 15K5):1283-1290. Results of large mulli
12. GERBER GS, THISTED R, CHODAK GW, THOMPSON IM: Disease-specific survival following routine prostate cancer screening by digital rectal examination: corrected patient classification [letter; comment]. JAMA (1993) 270(20):2437.
13. BELVILLE WD: Are Tic tumours different from incidental tumours found at autopsy? The risk and reality of overdetection. Seniin. Urol. Oncol. (1995) 13(3):181-186.
14. SCHRÖDER FH, VAN DC-K I, DE KONING HJ, VIS AN, HOEDEMAEKER RF, KRANSE R: Prostate cancer detection at low prostate-specific antigen./ Urol. (2000) 163(3):806-812.
15. HANKEY BF, FEUER EJ, CLEGG LX et al.: Cancer surveillance series: interpreting trends in prostate cancerpart I: Evidence of the effects of screening in recent prostate cancer incidence, mortality and survival rates.J. Natl. Cancer bist. (1999) 91(12):1017-1024.
16. GANN PU, HENNEKENS CH, STAMPFER MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA (1995) 273(4):2S9-294. Large retrospective study showing the relationship of serum PSA levels to future prostate cancer risk.
17. CARTER HB, EPSTEIN JI, CHAN D\V, FOZARD JL, PEARSON JD: Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA (1997) 277(18):1456-1460.
18. CARTER BS, BEATY TH, STEINBERG GD, GUILDS B, WALSH PC: Mendelian inheritance of familial prostate cancer. Proc. Nat!. Acad. Sei. USA (1992) 89(8):3367-3371.
19. GRONBERG H: Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer l (HPC1) locus. JAMA (1997) 278(15):1251-1255.
20. GRONBERG H, XU J, SMITH JR ct at.: Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. Cancer Res. (1997) 57(20:4707-4709.
21. KEETCH D\V, RICE JP, SUAREZ BK, CATALONA WJ: Familial aspects of prostate cancer: a case control study./ Urol. (.1995) 154(6):2100-2102.
22. WALSH PC: Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. J. Urol. (1998) l60(l):265-266.
23. MORTON RA, Jr. : Racial differences in adenocarcinotna of the prostate in North American men. Urology (1994) 44(5):637-645.
24. CATALONA WJ, SMITH DS, ORNSTEIN DK: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA (1997) 277(18):1452-1455. First demonstration that risk of prostate cancer among men with PSA levels of 2.5 - 4.0 ng/ml is significant.
25. CARTER HB, EPSTEIN JI, PARTIN AW: Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. £/ro/0£)>(1999) 53(0:126-130.
26. CATALONA WJ, RICHIE JP, DEKERNION JB et al.: Comparison of prostate-specific antigen concentration versus prostate-specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J. Urol. (1994) 152(6 Pt 0:2031-2036.
27. CARTER HB, PEARSON JD, METTER EJ ct a!.: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA (1992) 26?(l6):2215-2220.
28. SMITH DS, CATALONA WJ: Rate of change in serum prostate-specific antigen levels as a method for prostate cancer detection. J. Urol. (1994) 152(4):1163-1167.
29. ORNSTEIN DK, SMITH DS, RAO GS, BASLER J\V, RATLIFF TL, CATALONA \VJ: Biological variation of total, free and percent free serum prostate-specific antigen levels in screening volunteers. J. Urol. (1997) 157(6):2179-2182.
30. CARTER HB, EPSTEIN JI, CHAN DW, FOZARD JL, PEARSON JD: Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA (1997) 277(1S):1456-1460.
31. NADLER RB, HUMPHREY PA, SMITH DS, CATALONA WJ, RATLIFF TL: Effect of inflammation and benign prostatic hyperplasia on elevated serum prostatespecific antigen levels./ Urn!. (1995) 154(2 Pt l):407-413-
32. COOKSON MS, FLOYD MK, BALL TP, Jr., MILLER EK, SAROSDY MF: The lack of predictive value of prostatespecific antigen density in the detection of prostate cancer in patients -with normal rectal examinations and intermediate prostate-specific antigen levels. / Uwl. (1995) 154(3):1070-1073.
33. CATALONA WJ, BEISER JA, SMITH DS: Serum free prostate-specific antigen and prostate-specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J. Urol. (1997) 158(6):2l62-2l67.
34. OESTERLING JE, JACOBSEN SJ, CHUTE CG et al.: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA (1993) 270(7):860-864.
35. CATALONA WJ, SOUTHWICK PC, SLAWIN KM et al.: Comparison of percent free PSA, PSA density and age-specific PSA cutoffs for prostate cancer detection and staging. Urology (2IIOO) 5
36. LILJA H, COCKETT AT, ABRAHAMSSON PA: Prostatespecific antigen predominantly forms a complex with ctl-antichymotrypsin in blood. Implications for procedures to measure prostate-specific antigen in serum. Cancer (1992) 70(1 Suppl):230-234
37. STENMAN UH, LEINONEN J, ALFTHAN H, RANNIKKO S, TUHKANEN K, ALFTHAN O: A complex between prostate-specific antigen and al-antlchymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. (1991) 5KD:222-226.
38. ORNSTEIN DK, SMITH DS, HUMPHREY PA, CATALONA \VJ: The effect of prostate volume, age, total prostatespecific antigen level and acute inflammation on the percentage of free serum prostate-specific antigen levels in men without clinically detectable prostate cancer./ Urol. (1998) 15900:1234-1237.
39. CATALONA WJ, PARTIN AW, SLAWIN KM et al.: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA (1998) 279d9):1542-1547. Large multi
40. MARTINEZ M, ESPANA F, ROYO M eta!.: Prostate-specific antigen complexée to a(l)-antichymotrypsin in the early detection of prostate cancer. Ear. Urn!. (2000) 38(1):85-90.
41. BRAWER MK, CHELI CD, NEAMAN IE et a!.-. Complexed prostate-specific antigen provides significant enhancement of specificity compared with total prostate-specific antigen for detecting prostate cancer.J. Urol. (2000) 163(5):1476-1480.
42. PARTIN AW, KATTAN M\V, SUBONG EN et al.-. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA (1997) 277(18):1445-1451. Large multi-centre trial demonstrating the value of serum PSA levels. Gleason grade and digital rectal examination for clinical staging.
43. SOUTHWICK PC, CATALONA \VJ, PARTIN A\V et al.: Prediction of post-radical prostatectomy pathological outcome for stage Tic prostate cancer with percent free prostate-specific antigen: a prospective multicenter clinical trial. J. Urol. (1999) 162(4):1346-1351.
44. KATZ AE, DE VRIES GM, BEGG MD et ah. Enhanced reverse transcriptase-polymerase chain reaction for prostate-specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer (1995) 75(7):l642-l648.
45. MCNEAL JE, VILLERS AA, REDWINE EA, FREIHA FS, STAMEY TA: Histologie differentiation, cancer volume and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer (1990) 66(6):1225-1233.
46. OLUMI AF, RICHIE JP, SCHULTZ DJ, D'AMICO AV: Calculated volume of prostate cancer identifies patients with clinical stage TIC disease at high risk of biochemical recurrence-after radical prostatectomy: a preliminary study. Urology (2000) 56(2):273-277.
47. SCHMID HP, MCNEAL JE, STAMEY TA: Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of Increasing cancer volume. oiHC93) 71(6):2031-2040.
48. GERBER GS, GORNIK HL, GOLDFISCHER ER, CHODAK G\V, RUKSTALIS DB: Evaluation of changes in prostatespecific antigen in clinically localized prostate cancer managed without initial therapy. J. Urol. (1998) 159(4):1243-1246.
49. NAM RK, KLOTZ LH, JEWETT MA, DANJOUX C, TRACHTENBERG J: Prostate-specific antigen velocity as a measure of the natural history of prostate cancer: defining a 'rapid riser' subset. Br. J. Urol. (1998) 81(1):100-104.
50. STAMEY TA, YANG N, HAY AR, MCNEAL JE, FREIHA FS, REDWINE, E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl.J. Meet. (1987) 317(15):909-9l6.
51. PRUTH1 RS, JOHNSTONE I, TU IP, STAMEY.TA: Prostatespecific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologie characteristics of the primary cancer. Um!ogy(l997) 49(5):737-742.
52. PATEL A, DOREY F, FRANKLIN J, DEKERNION JB: Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate-specific antigen doubling times and log slope prostate-specific antigen./ Urol. (1997) 158(4):144l-l445.
53. PARTIN A\V, PEARSONJD, LANDIS PK eta!.: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant métastases. Urology (1994) 43(5):649-659-
54. ZAGARS GK, POLLACK A: Kinetics of serum prostatespecific antigen after external beam radiation for clinically localized prostate cancer. Radiother. Oncol. (1997)44(3):213-221.
55. CHAUVET B, FELIX-FAURE C, LUPSASCKA N et al.: Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy./ Clin. Oncol. (1994) 12(7):1402-1407.
56. CRITZ FA, LEVINSON AK, WILLIAMS WH, HOLLADAY CT, GRIFFIN VD, HOLLADAY DA: Prostate-specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy./ froJ. (1999) l6l(4):1199-1203. Large series establishing the PSA nadir associated with curative radiotherapy.
57. STAMEY TA, FERRARI MK, SCHMID HP: The value of serial prostate-specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients./ Urol. (1993) 150(6):1856-1859.
58. POLLACK A, ZAGARS GK, KAyADI VS.- Prostate-specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer (1994) 74(2):670-678.
59. FOWLER JE, Jr., PANDEY P, BRASWELL NT, SEAVER L: Prostate-specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer. Surgery (1W) Il6(2):302-305.
60. HANCOCK SL, COX RS, BAGSHAW MA: Prostate-specific antigen after radiotherapy for prostate cancer: a revaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University./ Urol. (1995) 154(4):1412-1417.
61. D'AMICO AV, HANKS GE: Linear regressive analysis using prostate-specific antigen doubling time for predicting tumour biology and clinical outcome in prostate cancer. Ci7Hcer(1993) 72(9):2o38-2643.
62. 1ANNUZZI CM, STOCK RG, STONE NN: PSA kinetics following 1-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer. Radiât. Oncol. Iiwcstig. (1999) 7(1)50-35.
63. SHINOHARA K, RHEE B, PRESTI JC, Jr., CARROLL PR: Cryosurgical ablation of prostate cancer: patterns of cancer recurrence./ Urol. (1997)158(6):2206-2209.
64. CONiNOLLY JA, SHINOHARA K, PRESTI JC, Jr., CARROLL PR: Prostate-specific antigen after cryosurgical ablation of the prostate. Defining the appropriate response. Urol. Clin. North Am. (1997) 24(2):415-420.
65. FOWLER JE, Jr., PANDEY P, SHAVER LE, FELIZ TP, BRASWELL NT: Prostate-specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer.J. Urol. (1995) 153(6):1860-1865. Study demonstrating the impact of androgen ablation on serum PSA levels.
66. DALTON DL: Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology (1989) 33(6):465.
67. NEAL DE, Jr., CLEJAN S, SARMA D, MOON TO: Prostatespecific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and non-human primate. Prostate (1992) 20(2):105-111.
68. HASUI Y, MARUTSUKA K, ASADA Y, IDE H, N1SHI S, OSADA Y: Relationship between serum prostatespecific antigen and histologies! prostatitis in patients with benign prostatic hyperplasia. Prostate (1994) 25(2):91-96.
69. YAMAMOTO M, HIBI H, MIYAKE K: Prostate-specific antigen levels in acute and chronic bacterial prostatitis. Hityokika Kiyo. (1993) 39(5):445-449.
70. IRANI J, LEV1LLAIN P, GOUJON JM, BON D, DORE B, ÄUERT J: Inflammation In benign prostatic hyperplasia: correlation with prostate-specific antigen value./ Urol. (1997) 157(4):1301-1303.
71. NICKEL JC, DOWNEY J, YOUNG I, BOAG S: Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJUInt. (1999) 84(9);976-981.
72. SEMJONOW A, ROTH S, HAMM M, RATHERT P: Re: Non-traumatic elevation of prostate-specific antigen following cardiac surgery and extracorporeal cardiopulmonary bypass [letter; comment]. / Urol. (1996) 155(l):295-296.
73. SPIRO LH, LABAY G, ORKIN LA: Prostatic infarction. Role in acute urinary retention. Urology (1974) 3(3):345-347.
74. BRAWN PN, FOSTER DM, JAY DW et al.: Characteristics of prostatic infarcts and their effect on serum prostate-specific antigen and prostatic acid phosphatase. J/ro/O£y(1994) 44(l):71-75.
75. GLENSKIWJ, KLEE GG, BERGSTRALH EJ, OESTERLING JE: Prostate-specific antigen: establishment of the reference range for the clinically normal prostate gland and the effect of digital rectal examination, ejaculation and time on serum concentrations. Prostate (1992) 21(2):99-110.
76. MCALEER JK, GERSON LW, MCMAHON D, GELLER L: Effect of digital rectal examination (and ejaculation) on serum prostate-specific antigen after twenty-four hours. A randomized, prospective study. Urology i\995~) 4l(2):lll-112.
77. DELIVELIOTIS C, ALJVIZATOS G, STAVROPOULOS NJ et al.: Influence of digital examination, cystoscopy, transrectal ultrasonography and needle biopsy on the concentration of prostate-specific antigen. Vrol. Int. (199-1) 53(4):186-190.
78. CRA\VFORD ED, SCHUTZ MJ, CLEJAN S et al.: The effect of digital rectal examination on prostate-specific antigen lev-els. JAMA (1992) 267(l6):2227-2228.
79. EL SHIRBINY AM, NILSON T, PAWAR HN: Serum prostate-specific antigen: hourly change/24 h compared with prostatic acid phosphatase. Urology (1990) 35(l):88-92.
80. HAGOOD PG, PARRA RO, RAUSCHER JA: Nontraumatic elevation of prostate-specific antigen following cardiac surgery and extracorporeal cardiopulmonary bypass./ Vrol. (1994) 152(6 Pt 1):2043-2045.
81. OESTERLING JE, RICE DC, GLENSKI \VJ, BERGSTRALH EJ: Effect of cystoscopy, prostate biopsy and transurethral resection of prostate on serum prostate-specific antigen concentration. £/rc>/o&y(1993) 42(3):27
82. YUAN JJ, COPLEN DE, PETROS JA et ah Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate-specific antigen levels./ Urol. (1992) 147(3 Pt 2):810-814.
83. BOSSENS MM, VAN STRAALEN JP, DE REIJKE TM, KURTH KH, SANDERS GT: Kinetics of prostate-specific antigen after manipulation of the prostate. Eur.J. Cfl;ccr(1995) 31A(5):682-685.
84. AUS G, SKUDE G: Effect of ultrasound guided core biopsy of prostate on scrum concentration of prostate-specific antigen and acid phosphatase activity. Scand.J. Urol. Nephrol. (1992) 26(l):21-23.
85. ORNSTEIN DK, RAO GS, SMITH DS, RATLIFF TL, BASLER J\V, CATALONA \VJ: Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate-specific antigen levels. / Urol. (1997) 157(1):195-198.
86. KIRKALI 2, KIRKALI G, ESEN A: Effect of ejaculation on prostate-specific antigen levels in normal men. Eitr. Urol. (1995) 27(4):292-294.
87. TCHETGEN MB, SONG JT, STRAWDERMAN M, JACOBSEN SJ, OESTERLING JE: Ejaculation increases the serum prostate-specific antigen concentration. Urology (1996) 47(4)011-516.
88. LEVENTHAL EK, ROZANSKI TA, MOREY AF, RHOLL V: The effects of exercise and activity on serum prostatespecific antigen levels./ Urol. (1993) 150(3);893-894.
89. GUESS HA, GORMLEY GJ, STONER E, OESTERLING JE: The effect of finasteride on prostate-specific antigen: review of available data./ Urol. (1996) 155(l):3-9-
90. ANDRIOLE GL, GUESS HA, EPSTEIN JI et al.: Treatment with finasteride preserves usefulness of prostatespecific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebocontrolled clinical trial. PLESS Study- Group. Proscar Long-term Efficacy and Safety Study. Urology (1998) 52(2):195-201.
91. KEETCH D\V, ANDRIOLE GL, RATLIFF TL, CATALONA \VJ: Comparison of percent free prostate-specific antigen levels in men -with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. Urology (1997) 50(6):901-905.
92. PANNEK J, MARKS IS, PEARSON JD et al.: Influence of finasteride on free and total serum prostate-specific antigen levels in men with benign prostatic hyperplasia.J. Urol. (1998) 159(2):44953.
93. BRAWER MK, LIN D\V, WILLIFORD WO, JONES K, LEPOR H: Effect of finasteride and/or terazosin on serum PSA: results of VA Co-operative Study #359. Prostate (1999) 39(4):234-239.
94. MARKS LS, PARTIN AW, EPSTEIN JI et al.: Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J. Urol. (2000) 163(5):1451-1456.